Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
The paper presents the data available in the literature on the efficacy and tolerability of basic tumor necrosis factor α inhibitors (TNF α) etanercept, adalimumab, infliximab in the treatment of psoriatic arthritis (PsA) and their effects on the major manifestations of this disease - cutaneous and...
Saved in:
Main Authors: | Vladimir Vasilyevich Badokin, I A Troshkina, Yu L Korsakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/326 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Golimumab in the treatment of psoriatic arthritis: efficacy and safety
by: Tatiana Viktorovna Korotaeva, et al.
Published: (2015-09-01) -
Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis
by: Tatiana Valentinovna Popkova, et al.
Published: (2012-12-01) -
PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva
Published: (2016-07-01) -
The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01) -
A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
by: N. S. Rudneva, et al.
Published: (2021-12-01)